Rhythm Pharmaceuticals, Inc.
RYTM
$59.93
-$0.25-0.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.94% | 72.61% | 47.76% | 51.28% | 126.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.94% | 72.61% | 47.76% | 51.28% | 126.41% |
| Cost of Revenue | 29.96% | 17.14% | 58.71% | 31.80% | 97.54% |
| Gross Profit | 25.46% | 81.15% | 46.44% | 53.85% | 130.49% |
| SG&A Expenses | 13.68% | 17.78% | 16.09% | 21.20% | 39.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.51% | 26.85% | 16.07% | 5.67% | 14.77% |
| Operating Income | 1.02% | 0.02% | 0.15% | 13.14% | 9.60% |
| Income Before Tax | 64.97% | -4.69% | -0.43% | 31.95% | -170.36% |
| Income Tax Expenses | -73.33% | -145.92% | -193.48% | -- | -- |
| Earnings from Continuing Operations | 64.99% | -3.98% | 1.18% | 30.92% | -170.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.99% | -3.98% | 1.18% | 30.92% | -170.94% |
| EBIT | 1.02% | 0.02% | 0.15% | 13.14% | 9.60% |
| EBITDA | 0.98% | -0.06% | 0.03% | 13.16% | 9.59% |
| EPS Basic | 65.72% | -3.06% | 3.73% | 33.02% | -155.47% |
| Normalized Basic EPS | 3.16% | -0.64% | 5.05% | 36.57% | 12.05% |
| EPS Diluted | 65.72% | -3.06% | 3.73% | 33.02% | -155.47% |
| Normalized Diluted EPS | 3.16% | -0.64% | 5.05% | 36.57% | 12.05% |
| Average Basic Shares Outstanding | 4.85% | 4.03% | 5.78% | 7.29% | 6.06% |
| Average Diluted Shares Outstanding | 4.85% | 4.03% | 5.78% | 7.29% | 6.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |